Biomea Fusion Presents New Translational Data at the European Association for the Study of Diabetes (EASD) 2022 in Animal Models and Ex-vivo Human Donor Islets Further Supporting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes

September 22, 2022

https://www.globenewswire.com/news-release/2022/09/22/2521117/0/en/Biomea-Fusion-Presents-New-Translational-Data-at-the-European-Association-for-the-Study-of-Diabetes-EASD-2022-in-Animal-Models-and-Ex-vivo-Human-Donor-Islets-Further-Supporting-BMF.html

REDWOOD CITY, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (Nasdaq:BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, presented “Oral long-acting menin inhibitor normalizes type 2 diabetes in two rat models” at the European Association for the Study of Diabetes Annual Meeting (EASD).

Read more at globenewswire.com

Related news for (BMEA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.